Trials that say “maybe”: the disconnect between exploratory and confirmatory testing after drug approval

Abstract

Clinical trials that explore the repurposing of drugs for off-label uses are common. But without a commitment to rigorously testing the hypotheses generated by these exploratory trials, patients are put in harm’s way, argue <b>Benjamin Carlisle and colleagues</b>